REFERENCES
1. Innocenti A., Melita D., Mori F., Ciancio F., Innocenti M. Management of gynecomastia in patients with different body types considerations on 312 consecutive treated cases. Ann Plast Surg. 2017; 78 (5): 492-6.
2. Kanakis G.A., Nordkap L., Bang A.K., Calogero A.E., Bártfai G., Corona G., et al. EAA clinical practice guidelines-gynecomastia evaluation and management. Andrology. 2019; 7 (6): 778-93. DOI: https://doi.org/10.1111/andr.12636
3. Giordano S.H., Cohen D.S., Buzdar A.U., Perkins G., Hortobagyi G.N. Breast carcinoma in men: a population-based study. Cancer. 2004; 101 (1): 51-7. DOI: https://doi.org/10.1002/cncr.20312
4. Dedov I.I., Mel’nichenko G.A., Fadeev V.V. Endocrinology. Moscow: GEOTAR-Media., 2007: 432 p. (in Russian)
5. Kamalov A.A., Pavlova Z. Sh., Gostriy A.V., Okhobotov D.A., Vasilevskiy R.P. Estrogen metabolites and their pathogenetic role in prostate cancer (review). Tekhnologii zhyvykh sistem [Living Systems Technologies]. 2016; 3 (1): 5-13. (in Russian)
6. Efremov E.A., Shekhovtsov S. Yu., Butov A.O., Khizriev Kh.Z., Kastrikin Yu.V., Tolstov I.S. A modern look at the physiological effects of testosterone in men. Eksperimental’naya i klinicheskaya urologiya [Experimental and Clinical Urology]. 2017; (3): 64-9. (in Russian)
7. Rohrmann S., Nelson W.G., Rifai N., Brown T.R., Dobs A., Kanarek N., et al. Serum estrogen, but not testosterone, levels differ between black and white men in a nationally representative sample of Americans. J Clin Endocrinol Metab. 2007; 92 (7): 2519-25. DOI: https://doi.org/10.1210/jc.2007-0028
8. Williams V.L., Awasthi S., Fink A.K., Pow-Sang J.M., Park J.Y., Gerke T., et al. African-American men and prostate cancer-specific mortality: a competing risk analysis of a large institutional cohort, 19892015. Cancer Med. 2018; 7 (5): 2160-71. DOI: https://doi.org/10.1002/cam4.1451
9. Basu A., Seth S., Arora K., Verma M. Evaluating estradiol levels in male patients with colorectal carcinoma. J Clin Diagn Res. 2015; 9 (1): BC 08-10. DOI: https://doi.org/10.7860/jcdr/2015/10508.5397
10. Montgomery R.B., Mostaghel E.A., Vessella R., Hess D.L., Kalhorn T.F., Higano C.S., et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res. 2008; 68 (11): 4447-54. DOI: https://doi.org/10.1158/0008-5472.can-08-0249
11. Jankowska E.A., Rozentryt P., Ponikowska B., Hartmann O., Kustrzycka-Kratochwil D., Reczuch K., et al. Circulating estradiol and mortality in men with systolic chronic heart failure. JAMA. 2009; 301 (18): 1892901. DOI: https://doi.org/10.1001/jama.2009.639
12. Nieschlag E., Finkelstein J. Testosterone: Action, Deficiency, Substitution. Berlin: Springer-Verlag, 1998: 187-207.
13. Ametov A.S., Pashkova E. Yu. Evolution of testosterone replacement therapy. New forms, new possibilities. Endokrinologiya: novosti, mneniya, obuchenie [Endocrinology: News, Opinions, Training]. 2017; 2 (19): 55-65. (in Russian)
14. Hess R.A. Estrogen in the adult male reproductive tract: a review. Reprod Biol Endocrinol. 2003; 1: 52. DOI: https://doi.org/10.1186/14777827-1-52
15. Guidelines on Male Hypogonadism. In: EAU Guidelines, presented on the 27th EAU Annual Congress. Paris, 2012.
16. Hess R.A., Carnes K. The role of estrogen in testis and the male reproductive tract: a review and species comparison. Anim Reprod. 2004; 1 (1).
17. Gill-Sharma M.K., Balasinor N., Parte P., Aleem M., Juneja H.S. Effects of tamoxifen metabolites on fertility of male rat. Contraception. 2001; 63 (2): 103-9.
18. Chua M.E., Escusa K.G., Luna S., Tapia L.C., Dofitas B., Morales M. Revisiting oestrogen antagonists (clomiphene or tamoxifen) as medical empiric therapy for idiopathic male infertility: a meta-analysis. Andrology. 2013; 1 (5): 749-57. DOI: https://doi.org/10.1111/j.20472927.2013.00107.x
19. Vandekerckhove P., Lilford R., Vail A., Hughes E. Clomiphene or tamoxifen for idiopathic oligo/asthenospermia. Cochrane Database Syst Rev. 2000; 2: CD 000151. DOI: https://doi.org/10.1002/14651858.CD 000151
20. Kim H.H., Schlegel P.N. Endocrine manipulation in male infertility. Urol Clin North Am. 2008; 35 (2): 303-18, x. DOI: https://doi.org/10.1016/j.ucl.2008.01.003
21. Rachdaoui N., Sarkar D.K. Pathophysiology of the effects of alcohol abuse on the endocrine system. Alcohol Res. 2017; 38 (2): 255-76.
22. Purohit V. Can alcohol promote aromatization of androgens to estrogens? A review. Alcohol. 2000; 22 (3): 123-7.
23. Cutolo M. Estrogen metabolites: increasing evidence for their role in rheumatoid arthritis and systemic lupus erythematosus. J Rheumatol. 2004; 31 (3): 419-21.
24. de Ronde W., de Jong F.H. Aromatase inhibitors in men: effects and therapeutic options. Reprod Biol Endocrinol. 2011; 9: 93. DOI: https://doi.org/10.1186/1477-7827-9-93
25. Weigel N.L., Moore N.L. Cyclins, cyclin dependent kinases, and regulation of steroid receptor action. Mol Cell Endocrinol. 2007; 265-266: 157-61. DOI: https://doi.org/10.1016/j.mce.2006.12.013
26. Kong E.H., Pike A.C., Hubbard R.E. Structure and mechanism of the oestrogen receptor. Biochem Soc Trans. 2003; 31 (pt 1): 56-9.
27. Nelson W.G., De Marzo A.M., DeWeese T.L., Isaacs W.B. The role of inflammation in the pathogenesis of prostate cancer. J Urol. 2004; 172 (5 pt 2): S 6-11; discussion S 11-2.
28. Prins G.S., Birch L., Couse J.F., Choi I., Katzenellenbogen B., Korach K.S. Estrogen imprinting of the developing prostate gland is mediated through stromal estrogen receptor alpha: studies with alphaERKO and betaERKO mice. Cancer Res. 2001; 61 (16): 6089-97.
29. Paruthiyil S., Parmar H., Kerekatte V., Cunha G.R., Firestone G.L., Leitman D.C. Estrogen receptor beta inhibits human breast cancer cell proliferation and tumor formation by causing a G2 cell cycle arrest. Cancer Res. 2004; 64 (1): 423-8.
30. Hartman J., Lindberg K., Morani A., Inzunza J., Strom A., Gustafsson J.A. Estrogen receptor beta inhibits angiogenesis and growth of T47D breast cancer xenografts. Cancer Res. 2006; 66 (23): 11 207-13. DOI: https://doi.org/10.1158/0008-5472.can-06-0017
31. Risbridger G.P., Ellem S.J., McPherson S.J. Estrogen action on the prostate gland: a critical mix of endocrine and paracrine signaling. J Mol Endocrinol. 2007; 39 (3): 183-8. DOI: https://doi.org/10.1677/jme-07-0053
32. Kuiper G.G., Carlsson B., Grandien K., Enmark E., Haggblad J., Nilsson S., et al. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology. 1997; 138 (3): 863-70. DOI: https://doi.org/10.1210/endo.138.3.4979
33. Tazhetdinov O. Kh. Features of diagnosis and treatment of infertility in obese men: Diss. Moscow, 2012. (in Russian)
34. Schwartz V. Ya. Inflammation of adipose tissue Problemy endokrinologii [Problems of Endocrinology]. 2009; 55 (4, 5, 6): 44-9, 43-8, 40-5. (in Russian)
35. Santen R.J., Samojlik E., Lipton A., Harvey H., Ruby E.B., Wells S.A., et al. Kinetic, hormonal and clinical studies with aminoglutethimide in breast cancer. Cancer. 1977; 39 (6 suppl): 2948-58.
36. Santen R.J., Santner S., Davis B., Veldhuis J., Samojlik E., Ruby E. Aminoglutethimide inhibits extraglandular estrogen production in postmenopausal women with breast carcinoma. J Clin Endocrinol Metab. 1978; 47 (6): 1257-65. DOI: https://doi.org/10.1210/jcem-47-6-1257
37. Ribeiro M.A., Gameiro L.F., Scarano W.R., Briton-Jones C., Kapoor A., Rosa M.B., et al. Aromatase inhibitors in the treatment of oligozoospermic or azoospermic men: a systematic review of randomized controlled trials. JBRA Assist Reprod. 2016; 20 (2): 82-8. DOI: https://doi.org/10.5935/1518-0557.20160019
38. Helo S., Ellen J., Mechlin C., Feustel P., Grossman M., Ditkoff E., et al. A randomized prospective double-blind comparison trial of clomiphene citrate and anastrozole in raising testosterone in hypogonadal infertile men. J Sex Med. 2015; 12 (8): 1761-9. DOI: https://doi.org/10.1111/jsm.12944
39. Kumar R. Medical management of non-obstructive azoospermia. Clinics (Sao Paulo). 2013; 68 (suppl 1): 75-9.
40. Hall J.M., Couse J.F., Korach K.S. The multifaceted mechanisms of estradiol and estrogen receptor signaling. J Biol Chem. 2001; 276 (40): 36 869-72. DOI: https://doi.org/10.1074/jbc.R 100029200
41. Ascenzi P., Bocedi A., Marino M. Structure-function relationship of estrogen receptor alpha and beta: impact on human health. Mol Aspects Med. 2006; 27 (4): 299-402. DOI: https://doi.org/10.1016/j. mam.2006.07.001
42. Meegan M.J., Lloyd D.G. Advances in the science of estrogen receptor modulation. Curr Med Chem. 2003; 10 (3): 181-210.
43. Dowers T.S., Qin Z.H., Thatcher G.R., Bolton J.L. Bioactivation of Selective Estrogen Receptor Modulators (SERMs). Chem Res Toxicol. 2006; 19 (9): 1125-37. DOI: https://doi.org/10.1021/tx060126v
44. Loves S., Ruinemans-Koerts J., de Boer H. Letrozole once a week normalizes serum testosterone in obesity-related male hypogonadism. Eur J Endocrinol. 2008; 158 (5): 741-7. DOI: https://doi.org/10.1530/eje-07-0663
45. Cavallini G., Beretta G., Biagiotti G. Preliminary study of letrozole use for improving spermatogenesis in non-obstructive azoospermia patients with normal serum FSH. Asian J Androl. 2011; 13 (6): 895-7. DOI: https://doi.org/10.1038/aja.2011.44
46. Shoshany O., Abhyankar N., Mufarreh N., Daniel G., Niederberger C. Outcomes of anastrozole in oligozoospermic hypoandrogenic subfertile men. Fertil Steril. 2017; 107 (3): 589-94. DOI: https://doi.org/10.1016/j.fertnstert.2016.11.021
47. Saylam B., Efesoy O., Cayan S. The effect of aromatase inhibitor letrozole on body mass index, serum hormones, and sperm parameters in infertile men. Fertil Steril. 2011; 95 (2): 809-11. DOI: https://doi.org/10.1016/j.fertnstert.2010.09.021
48. Dias J.P., Melvin D., Simonsick E.M., Carlson O., Shardell M.D., Ferrucci L., et al. Effects of aromatase inhibition vs. testosterone in older men with low testosterone: randomized-controlled trial. Andrology. 2016; 4 (1): 33-40. DOI: https://doi.org/10.1111/andr.12126
49. Ferlay J., Soerjomataram I., Dikshit R., Eser S., Mathers C., Rebelo M., et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015; 136 (5): E 359-86. DOI: https://doi.org/10.1002/ijc.29210
50. Fragkaki A.G., Angelis Y.S., Koupparis M., Tsantili-Kakoulidou A., Kokotos G., Georgakopoulos C. Structural characteristics of anabolic androgenic steroids contributing to binding to the androgen receptor and to their anabolic and androgenic activities. Applied modifications in the steroidal structure. Steroids. 2009; 74 (2): 172-97. DOI: https://doi.org/10.1016/j. steroids.2008.10.016
51. Covey D.F., Hood W.F. A new hypothesis based on suicide substrate inhibitor studies for the mechanism of action of aromatase. Cancer Res. 1982; 42 (8 suppl): 3327s-33s.
52. Van Asten K., Neven P., Lintermans A., Wildiers H., Paridaens R. Aromatase inhibitors in the breast cancer clinic: focus on exemestane. Endocr Relat Cancer. 2014; 21 (1): R 31-49. DOI: https://doi.org/10.1530/erc-13-0269
53. Smith I.E., Norton A. Fadrozole and letrozole in advanced breast cancer: clinical and biochemical effects. Breast Cancer Res Treat. 1998; 49 (suppl 1): S 67-71; discussion S 73-7.
54. Butaney M., Thirumavalavan N., Balasubramanian A., McBride J.A., Gondokusumo J., Pastuszak A.W., et al. Treatment of estrogen levels in the management of hypogonadism: an anonymous survey of ISSM members. Urology. 2020; 139: 104-9. DOI: https://doi.org/10.1016/j. urology.2020.01.032